The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

INTRODUCTION - We sought to investigate the impact of fatty liver disease (FLD) on prostate cancer (PCa) screening by estimating the odds of having a prostate-specific antigen (PSA) value over the cutoff used to prompt for the recommendation of prostate biopsy.

METHODS - Between 2007 and 2013, 18 533 native Korean men eligible to receive a serum PSA test, liver profiles, and abdominal ultrasonography were recruited. Logistic regression was used to estimate the odds of an abnormal PSA (≥2. 5 ng/mL) in these men (age 45-75 years, PSA≤10 ng/mL) in relation to FLD. The FLD status was categorized as normal, mild, moderate, and severe grade by abdominal sonography.

RESULTS - A total of 16 563 men (89. 4%) were included in the study after applying the inclusion criteria. Liver profiles were negatively correlated with the serum PSA level. After controlling for age and obesity, there was a statistically significant trend towards a lower likelihood of having a serum PSA level of ≥2. 5 ng/mL with severe FLD, having a 34. 7% lower likelihood (odds ratio 0. 653, 95% confidence interval 0. 477-0. 88; p<0. 01) compared to men in the normal group.

CONCLUSIONS - Severe FLD is an independent predictor of a lower likelihood of having abnormal PSA level. Further studies are needed to better define these results in clinical biopsy practice.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2015 Dec 14 [Epub]

Jong Hyun Yoon, Hee Jo Yang, Jae Heon Kim, Seung Whan Doo, Won Jae Yang, Jiyoung Hwang, Seong Sook Hong, Suyeon Park, Dae Yeon Cho

Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;, Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;, Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;, Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;, Department of Urology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;, Department of Radiology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;, Department of Radiology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea;, Department of Biostatistics, Soonchungyang University, College of Medicine, Seoul, Republic of Korea;, Department of Urology, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe